ArteraAI stands out in the precision medicine industry with its AI-derived prognostic biomarker test, the first and only of its kind to be endorsed as a risk stratification tool in the NCCN Clinical Practice Guidelines for Prostate Cancer. This AI-enabled test, developed from five Phase III randomized trials, offers personalized therapy options by accurately predicting and prognosticating patient outcomes in localized prostate cancer. ArteraAI's unique approach to precision medicine and its recognition by a reputable cancer network demonstrate its industry leadership and technical prowess.